Trials / Completed
CompletedNCT01507454
Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,613 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Europe. The aim of this study is to investigate the self-reported impact of Vagifem® (estradiol) treatment on urogenital discomfort in women with atrophic vaginitis due to oestrogen deficiency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | estradiol, 25 mcg | Vaginal tablets for 6-12 weeks according to product labelling |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2012-01-11
- Last updated
- 2017-02-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01507454. Inclusion in this directory is not an endorsement.